Dyne Therapeutics依据纳斯达克规则5635(c)(4)向14名新员工授予激励股权
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics向14名新入职员工授予激励股权，包括可购买最多278,100股普通股的非合格股票期权，行权价等于2026年9月15日纳斯达克全球精选市场收盘价，以及88,400股限制性股票单位。期权期限十年、四年内归属，限制性股票单位自入职日起四年内分四次等额年度归属，均以员工持续服务为条件。
WALTHAM, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 14 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 278,100 shares of Dyne’s common stock at a per share exercise price equal to the closing price of Dyne’s common stock on The Nasdaq Global Select Market on September 15, 2026, and restricted stock units with respect to an aggregate of 88,400 shares of Dyne’s common stock. The stock options have a ten-year term and are scheduled to vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and the remainder vesting in 12 equal quarterly installments thereafter, subject to such employee’s continued service to Dyne through the applicable vesting dates. The restricted stock units are scheduled to vest over four years from the applicable employee’s start date in four equal annual installments, subject to such employee’s continued service to Dyne through the applicable vesting dates.
The inducement equity awards are subject to the terms and conditions of award agreements covering the grants and Dyne’s 2024 Inducement Stock Incentive Plan.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
来源：Dyne Therapeutics｜戴恩 · investors.dyne-tx.com